BronchogenvsPinealon

Bronchogen is a Khavinson tetrapeptide (Ala-Glu-Asp-Leu) positioned as the respiratory-system bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the family-wide framework: tissue-derived short peptides preferentially target the same tissue type from which they were originally identified, binding to gene promoter sequences and modulating expression of tissue-specific genes.

For bronchogen, proposed targets include genes regulating bronchial epithelial cell proliferation and differentiation, surfactant production by alveolar type II cells, ciliary function in airway epithelium, and local immune regulation in respiratory mucosa. Russian research has reported bronchogen-induced improvements in lung function markers in animal models of chronic respiratory injury and in elderly populations with age-related pulmonary decline. Cellular studies have suggested effects on mucociliary clearance and reductions in airway inflammation markers.

As with all Khavinson cytogens and cytamins, the evidence base is concentrated in Russian gerontology and pulmonology research traditions with limited independent Western validation. Bronchogen is not a substitute for evidence-based treatment of asthma, chronic obstructive pulmonary disease, or other diagnosed respiratory conditions, and its role in respiratory health should be considered exploratory rather than established. The brief plasma half-life (around 30 minutes) reflects the family-wide model of transient signalling triggering longer-lasting transcriptional effects.

Pinealon is a short tripeptide (Glu-Asp-Arg) belonging to the Khavinson family of peptide bioregulators — small peptides hypothesised to regulate gene expression in tissue-specific ways by binding directly to DNA promoter regions. Pinealon is the brain- and pineal-gland-targeted member of this family, designed to penetrate cells and the nuclear membrane to interact with promoter sequences of genes involved in neuronal function and circadian regulation.

Proposed mechanisms include modulation of melatonin synthesis pathways (via effects on pineal gland function), upregulation of antioxidant defence enzymes in neurons, and protection against oxidative stress from age-related accumulation of reactive oxygen species. Russian preclinical studies have reported pinealon-induced increases in expression of genes involved in serotonin and melatonin metabolism, neurotrophic factor signalling, and antioxidant capacity, alongside protective effects against neurotoxin-induced neuronal damage in animal models.

The extremely short plasma half-life (around 30 minutes) is a feature shared with all Khavinson tripeptides — the proposed model is that the peptides act as transient signalling molecules that trigger longer-lasting changes in gene expression, with effects persisting well beyond plasma clearance. This model would explain the use of pulse-dosing protocols (10-30 day courses repeated periodically) rather than continuous administration. Importantly, almost all published efficacy data comes from Russian research groups associated with the original Khavinson laboratory, and the bioregulator framework has not been independently validated in Western clinical settings. Mechanistic claims should be treated as preliminary, and clinical use remains largely anecdotal outside Russia.